Over 52 weeks, weekly tirzepatide significantly increased MASH resolution without fibrosis worsening in biopsy-confirmed MASH with F2–F3 fibrosis. It also showed improvement of at least one fibrosis stage without worsening MASH. cT1 was significantly reduced in the treatment group compared to placebo, showing a dose-dependent reduction.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?